2022—Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) TCR and BCR kits, a family of multiplex-PCR, NGS-based assays that enable profiling of up to all seven T ...
TAC T-cell therapy is a new cancer treatment option. Researchers are studying it to treat both solid tumors and blood cancers, including multiple myeloma. If it gets FDA approval, this treatment would ...
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter® ...
This article and associated images are based on a poster originally authored by Alex Chenchik, Lester Kobzik, Tianbing Liu, Dongfang Hu, Kitt Paraiso, Khadija Ghias, and Paul Diehl and presented at ...
The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...
Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars ...
Cancer immunotherapy approaches such as adoptive transfer of chimeric antigen receptor (CAR) T cells or tumor-infiltrating lymphocytes have yielded promising results in hematological malignancies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback